Hormonersatztherapie und Prävention gemäß S3-Leitlinie-Reference-Cited by-同舟云学术

Hormonersatztherapie und Prävention gemäß S3-Leitlinie

Published:2020-02-12 Issue:S2 Volume:53 Page:161-166
ISSN:0017-5994
Container-title:Der Gynäkologe
language:de
Short-container-title:Gynäkologe

Author:

Windler E.,Hadji P.,Ortmann O.

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology

Link

http://link.springer.com/content/pdf/10.1007/s00129-020-04568-5.pdf

Reference36 articles.

1. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R, Farrell R (2016) ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. Obstet Gynecol 127(3):e93–e96

2. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators (2006) Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125–137

3. Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L (2016) Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 23(6):593–599

4. Budoff MJ, Chen GP, Hunter CJ, Takasu J, Agrawal N, Sorochinsky B, Mao S (2005) Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. J Womens Health 14(5):410–417

5. Cannoletta M, Cagnacci A (2014) Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health 1(6):745–757